CanSino Biologics Inc. announced that, the phase I clinical trial for the Absorbed Tetanus Vaccine developed by the Company, was officially initiated recently and the first trial patient case has been formally enrolled. The Absorbed Tetanus Vaccines is fermented with animal-free culture medium and safer, and the stable industrial scale processes have been identified. This vaccine is mainly used for non-neonatal tetanus prevention, which will further enrich the Company's product pipeline and enhance its core competitiveness.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.82 HKD | +2.51% | +14.06% | -20.08% |
Apr. 22 | Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine | MT |
Apr. 22 | Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.08% | 1.1B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
-9.14% | 11.95B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- 6185 Stock
- News CanSino Biologics Inc.
- CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine